Abeona Therapeutics vs TuHURA Biosciences
Free cash flow was −$84 million at Abeona Therapeutics and −$28 million at TuHURA Biosciences.
Side by side
| Abeona Therapeutics | TuHURA Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $0M |
| Revenue growth | — | — |
| Revenue growth a year, last 5 years | −10.3% | — |
| Gross margin | 73.7% | — |
| Operating margin | −1,536.9% | — |
| Net margin | 1,223.1% | — |
| Free cash flow | −$84M | −$28M |
| Free cash flow margin | −1,448.5% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 61.1% | 156.8% |
| Last close | $2.45 | $1.36 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $3.5 million | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Abeona TherapeuticsTuHURA Biosciences
Operating margin
Percent of revenue
Abeona TherapeuticsTuHURA Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Abeona TherapeuticsTuHURA Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Abeona Therapeutics and TuHURA Biosciences pages.